1. Home
  2. ACRS vs TAYD Comparison

ACRS vs TAYD Comparison

Compare ACRS & TAYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$3.08

Market Cap

230.8M

Sector

Health Care

ML Signal

HOLD

Logo Taylor Devices Inc.

TAYD

Taylor Devices Inc.

N/A

Current Price

$59.57

Market Cap

132.1M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
ACRS
TAYD
Founded
2012
1955
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
230.8M
132.1M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
ACRS
TAYD
Price
$3.08
$59.57
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$9.75
N/A
AVG Volume (30 Days)
1.3M
5.9K
Earning Date
11-06-2025
01-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.72
Revenue
$15,742,000.00
$44,593,219.00
Revenue This Year
N/A
$10.81
Revenue Next Year
$6.06
$8.37
P/E Ratio
N/A
$21.68
Revenue Growth
N/A
N/A
52 Week Low
$1.05
$29.50
52 Week High
$3.48
$58.95

Technical Indicators

Market Signals
Indicator
ACRS
TAYD
Relative Strength Index (RSI) 57.83 73.16
Support Level $3.12 $55.32
Resistance Level $3.48 $52.00
Average True Range (ATR) 0.21 2.37
MACD -0.01 0.93
Stochastic Oscillator 57.06 87.54

Price Performance

Historical Comparison
ACRS
TAYD

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

About TAYD Taylor Devices Inc.

Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.

Share on Social Networks: